Trials / Not Yet Recruiting
Not Yet RecruitingNCT07273942
Remote Ischemic Postconditioning in Septic Shock
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 720 (estimated)
- Sponsor
- Hospices Civils de Lyon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Septic shock is a leading cause of death worldwide despite intensive research efforts. Only a few interventions have been proven to be effective in improving patient-centered outcomes. Recent clinical trials have reported the safety and efficacy of remote ischemic postconditioning (RIPOST) in a variety of pathologies, including myocardial infarction, cardiac surgery, and stroke. While RIPOST was mainly tested in pathologies with low mortality rates, several follow-up studies of large randomized clinical trials in acute myocardial infarction and in patients undergoing coronary artery bypass surgery have reported significant decreases (\> 50%) in long-term mortality. Experimental studies and proof-of-concept clinical trials have also suggested the potential benefits of RIPOST on mortality in sepsis and septic shock. The present protocol aims to test whether this non-invasive, widely available, inexpensive, and innovative intervention can improve survival in septic shock.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Remote ischemic conditioning | A brachial cuff is positioned around one arm of the patient. Remote ischemic conditioning consists of alternating inflations and deflations of the brachial cuff. Four cycles of ischemic conditioning (5-min brachial cuff inflation at 200 mmHg followed by 5-min cuff deflation) are started as soon as possible after inclusion. The intervention is repeated 12 and 24 hours after inclusion. |
| OTHER | No intervention | No intervention will be performed in the conrol group |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2028-07-01
- Completion
- 2028-07-01
- First posted
- 2025-12-10
- Last updated
- 2026-01-28
Locations
23 sites across 1 country: France
Source: ClinicalTrials.gov record NCT07273942. Inclusion in this directory is not an endorsement.